Side effects of cholesterol medicine
Pro Research Analysisby 
Searched over 200M research papers
Side Effects of Cholesterol Medicine
Common Side Effects of Lipid-Lowering Drugs
Cholesterol medications, while effective in reducing serum cholesterol and triglycerides, often come with a range of side effects. The most frequently reported side effects are gastrointestinal symptoms, which are usually self-limited and reversible1. These include nausea, diarrhea, and abdominal pain.
Statins: Myopathy and Hepatic Injury
Statins, such as simvastatin and pravastatin, are widely used to lower LDL cholesterol by inhibiting HMG-CoA reductase. However, they can cause myopathy, a condition characterized by muscle pain and weakness, and in severe cases, rhabdomyolysis, which is the breakdown of muscle tissue1 4. Hepatic injury is another potential side effect, necessitating regular monitoring of liver enzymes during treatment1 5.
Injection Site Reactions and Elevated Liver Enzymes with Mipomersen
Mipomersen, used for severe LDL-hypercholesterolemia, has been associated with moderate to severe injection site reactions and elevated liver enzymes. These side effects led to discontinuation in several patients during clinical trials2.
Niacin: Flushing and Glycemic Control
Niacin, often used in combination with statins, can cause flushing, a common and uncomfortable side effect. Additionally, it may affect glycemic control, particularly in diabetic patients, although these effects tend to stabilize over time4 9.
PCSK9 Inhibitors: Alirocumab and Evolocumab
PCSK9 inhibitors like alirocumab and evolocumab are newer agents that significantly reduce LDL cholesterol levels. However, they are associated with injection site reactions, myalgia (muscle pain), neurocognitive events, and ophthalmologic events3 6. Despite these side effects, they have shown promise in reducing cardiovascular events in high-risk patients6.
Combination Therapies: Simvastatin Plus Niacin
Combination therapies, such as simvastatin plus niacin, have been shown to be effective and generally well-tolerated. Side effects in these combinations are similar to those observed with monotherapies, including gastrointestinal upset, muscle aches, and mild liver enzyme elevations4.
Long-Term Safety and Efficacy
Long-term studies indicate that while some cholesterol-lowering drugs have been used for over 20 years without serious side effects, continuous monitoring is essential. This is particularly important for newer medications, where long-term data is still being gathered1 7.
Conclusion
Cholesterol medications are effective in managing hyperlipidemia and reducing cardiovascular risk, but they come with a range of potential side effects. These include gastrointestinal symptoms, myopathy, hepatic injury, injection site reactions, and more. Regular monitoring and patient-specific adjustments are crucial to managing these side effects and ensuring the safe use of these medications.
Sources and full results
Most relevant research papers on this topic
A Comparative Review of the Adverse Effects of Treatments for Hyperlipidaemia
Lipid-lowering drugs effectively reduce cholesterol and triglycerides, but potential harmful side effects must be considered.
Literature ReviewEffect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
Mipomersen significantly reduces LDL-cholesterol in patients on maximal lipid-lowering drug therapy and regular apheresis, but is often associated with side effects.
RCTThree Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab.
Statins, Ezetimibe, and Evolocumab effectively lower cholesterol levels by targeting key molecules in lipid metabolism, and combining them with statins may reduce side effects and achieve optimal cholesterol levels.
Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).
Simvastatin plus niacin effectively reduce atherosclerosis progression and are well-tolerated in patients with coronary artery disease and low HDL cholesterol.
RCT
Highly CitedRandomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
Simvastatin significantly lowers LDL cholesterol, VLDL cholesterol, and IDL cholesterol, but not triglyceride levels, and may have a marginal effect on thrombogenic pathways.
RCTHighly CitedEfficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Alirocumab significantly reduced LDL cholesterol levels and showed a reduction in cardiovascular events when added to statin therapy at the maximum tolerated dose for 78 weeks.
RCT
Large Human Trial
Rigorous JournalHighly CitedRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Long-term simvastatin treatment is safe and improves survival in coronary heart disease patients, with a 37% reduction in the risk of undergoing myocardial revascularization procedures.
RCTLarge Human TrialHighly CitedHypercholesterolemia
Combination therapy of low-dose pravastatin and squalene effectively reduces total cholesterol and LDL cholesterol and increases HDL cholesterol in elderly patients with hypercholesterolemia, while reducing side effects.
RCTHighly CitedEfficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Fibrates reduce major coronary events and increase HDL-C levels without significant toxicity, while niacin has a more potent effect on HDL-C levels.
Meta-AnalysisHighly CitedEvaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
Anacetrapib treatment reduces LDL cholesterol and increases HDL cholesterol, with minimal side effects and low drug levels persisting up to 4 years after discontinuing treatment.
RCTLarge Human TrialHighly Cited